Monoclonal Anti-Septin 9 antibody produced in rat, approx. 1.0 mg/mL, clone Clone 1A6C2

Not available outside of the UK & Ireland.

Application

Monoclonal Anti-Septin 9 has been used in: immunoblottingimmunocytochemistryimmunohistochemistryimmunofluorescence

Biochem/physiol Actions

Septin 9 (SEPT9) has been implicated in tumorigenesis. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. In addition, SEPT9 is shown to be a DNA methylation-based biomarker, effectively discriminated colorectal cancer from normal specimens.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Monoclonal Anti-Septin 9 (rat IgG2a isotype) is derived from the hybridoma 1A6C2 produced by the fusion of mouse myeloma cells and splenocytes from rat immunized with a synthetic peptide of corresponding to the N-terminus of rat Septin 9, conjugated to KLH. Septin 9 (SEPT9) is a member of the septin family (also designated MSF/eseptin/Sint1). This gene is mapped to human chromosome 17q25.

Immunogen

synthetic peptide of corresponding to the N-terminus of rat Septin 9 conjugated to KLH

Physical form

Solution in 0.01M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.